Abstract
OBJECTIVE: Tamoxifen is commonly used for the adjuvant treatment after chemotherapy or metastatic disease in women with hormone receptor-positive breast cancer. Clinical profiles during tamoxifen therapy have not been evaluated in patients who took GnRH agonist injection for ovarian protection. Therefore, this study was conducted to evaluate menstrual patterns, hormonal profiles and endometrial effects in tamoxifen-treated premenopausal breast cancer patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
